

Table S1. Comprehensive Baseline Data Table														
Dose level	NO.	Age/ sex	prior lines of therapy	Refractory	Previous autoSCT	Previous alloSCT	BM blasts (% by morphology)	BM blasts (% by FCM)	CNS blasts (% by FCM)	EMD	Genetic Aberrations	Immunophenotypes	CD7 Expression (%)	
1×10 ⁻⁴ (+30%) kg	001	T-LBL	F/72	3	N	N	62	67.86	0	Mediastinum	IDH2, NRAS, PTPN11, KMT2D	CD2, CD7, CD117, CD38,	95	
	002	T-LBL	M/40	2	N	N	Y	1.5	2.3	0	Diffused	ND	CD7, CD33, CD34, CD56, CD99, CD38, CD5dim, TDT, 123dim	90
	003	T-LBL	M/28	2	N	N	N	6.5	0.37	0.37	Diffused	FBXW7, TNFRSF13B, KMT2D, NOTCH1	CD2, CD5, CD7, CD10, CD99, TDT	97.9
	004	T-LBL	F/57	2	N	N	N	1.5	4.7	0	Diffused	ND	CD3, CD7, CD99	90
	005	T-LBL	M/53	2	N	Y	N	25.5	37.39	25	Mediastinum	TP53, NRAS, CDKN2A, DNMT3A, IKZF1, NOTCH1, PTEN, BCOR, KMT2D	CD2, CD5, CD7, CD117, CD99dim, CD56dim	98.4
	006	SS	M/56	3	N	N	N	14	11.87	0	Diffused	CARD11, PRKCB, ARID1A, CTNNB1, SAMHD1	CD2, CD4, CD5, CD7, TCR α , TRBC1	98.36
	007	T-LBL	M/31	4	N	Y	Y	0	0	0	Mediastinum	PTPN11, SETD2, NOTCH1, VHL, BCOR, ADAMTS13, DIS3	CD7, CD99, CD33, CD38, TDT, CD56dim	98
	008	T-LBL	M/18	3	N	N	N	53	20.79	0	Diffused	GATA3, JAK3	CD7, CD99, TDT, CD28dim, CD34dim, CD56dim, CD3dim	99.5
	009	T-LBL	M/29	3	N	N	Y	84.5	85.61	13.6	Diffused	ND	cCD3, CD7, CD56, CD56dim, CD99dim, TDTdim	89.6
	010	T-LBL	M/32	4	N	N	Y	94	49.21	4.32	No	NOTCH1, ASXL1, NR3C1	cCD3, CD2, CD5, CD7, CD1a, CD38, TDT, CD3dim, CD8dim	95
5×10 ⁻⁴ (+30%) kg	011	T-LBL	F/31	2	Y	N	N	0	0.4	0	Diffused	PTEN, TNFRSF13B	CD2, CD3, CD5, CD7, CD1a, CD38, CD56, CD48dim, HLA-DRdim	100
	012	HSTCL	M/19	3	N	N	Y	0	1.57	0	Diffused	STAT5B	cCD3, CD2, CD3, CD7, CD56, CD38, TCR γ	90
	013	T-LBL	M/39	2	Y	N	N	21	95.76	0	Diffused	NOTCH1, PHF6, MED1, DNMT3A, ND	cCD3, CD5, CD7, CD99, TDT, CD56, CD38, HLA-DR, CD2dim, CD34dim, CD33dim	95.8
	014	T-LBL	M/31	4	N	N	N	0	0	0	Diffused	ND	cCD3, CD7, CD99, CD5, TDT, CD38, CD117dim, HLA-DRdim	98.3
	015	MEITL	F/53	2	N	N	N	0	0	0	Intestinal tract, bulky disease*	JAK3, STAT5B, CREBBP, EP300, KDM6A	CD7, CD38dim, CD38dim	90
	016	T-LBL	M/32	3	N	N	Y	0	0	5.98	Diffused, bulky disease*	ND	CD5, CD7, CD38, cCD3, TDT, CD99, CD34dim	90
	017	T-LBL	M/35	4	N	N	Y	98.5	98.42	0	No	KRAS, NOTCH1	CD3, CD7, CD99, TDT, CD117, CD33, CD38, CD5dim	97.4
	018	T-LBL	M/29	3	N	N	Y	1.5	3.6	0	Back of the eye, the face	JAK1, RBL1, KIT	CD3, CD5, CD7, CD99, TDTdim	90
	019	T-LBL	M/28	3	N	N	Y	0.5	0.12	34.81	No	KRAS, NOTCH1, PHF6, ERG, FAT4	CD7, CD33, CD11b, CD34, CD38, cCD3, CD5dim, CD117dim	99
	020	CTCL	F/34	3	N	N	N	1	1.2	0	Diffused	ND	CD2, CD3, CD7, CD8	90
1×10 ⁻⁵ (+30%) kg	021	T-LBL	F/46	3	N	N	N	90	91.25	44.12	Diffused	PHF6, SETD2, PTEN	CD5, CD7, CD99, cCD3, TDTdim, CD34dim	98.6
	022	T-LBL	F/30	3	N	Y	N	25.5	8.06	0	No	ND	CD7, CD99, CD34, CD38, cCD3, CD5dim	97.5
	023	T-LBL	M/25	3	N	N	Y	2	1.3	0	Diffused	JAK3, JAK1, BCL11B, ATM, NR3C1, STAG2	CD7, CD38, CD3, CD5dim	90
	024	T-LBL	F/24	4	N	N	N	2	0.7	0	Diffused	NRAS, PHF6, RUNX1, ARID5B, DIS3, EZH2, PTPRK	CD5, CD7, CD99, CD38, cCD3	90
	025	T-LBL	M/22	3	N	N	N	13	12	0	Diffused	ATM	CD2, CD5, CD3, CD7, CD99, CD1a, CD48dim	95.1
	026	T-LBL	M/33	3	N	Y	N	85	66.5	0	No	KRAS, NOTCH1	CD2, CD5, CD7, CD38, CD56, cCD3, CD48dim	99.3
	027	T-LBL	F/20	3	N	N	Y	0	0	0	Diffused	CD2, CD5, CD7, CD8, CD1adim	CD2, CD5, CD3, CD7, CD1a, TDT, CD38, CD48dim	90
	028	T-LBL	F/31	3	N	N	N	38	25.6	13.64	Diffused	PIK3CA, ARID1A, CDKN2B, DNMT3A, TET2, PRDM14, PCLQ, PRDM1, FBXO11	CD5, CD7, TDT, CD56	90
	029	T-LBL	M/40	4	N	N	Y	0	0	0	Diffused	ND	CD5, CD7, CD34, TDT, CD38, CD33, CD99	90
	030	T-LBL	F/67	2	N	N	N	15	3.2	0	No	ND	CD5, CD7, TDT, CD56	90
1×10 ⁻⁵ (+30%) kg	031	T-LBL	M/27	3	N	N	N	0	0.2	0	Diffused	ND	CD5, CD7, CD3, CD34dim, CD99dim	98.6
	032	T-ALL	F/47	2	Y	N	N	74.5	38.18	0	No	ND	CD7, CD99, CD38, CD33, CD5dim, CD10dim, CD34dim	98.8
	033	T-LBL	M/18	5	N	Y	N	13.5	36.22	0	Diffused	ND	CD7, CD38, CD5dim, CD99dim, CD56dim, CD33dim, CD48dim	91.3
	034	T-LBL	M/20	2	N	N	Y	0	0	0	Testicle	FBXW7, PHF6, NOTCH1	CD2, CD3, CD5, CD9, CD99, CD38, CD34dim, CD5dim	90
	035	T-ALL	M/49	4	N	N	Y	1.5	0.07	0.03	Diffused	NRAS, PHF6, WT1, FBXW7, IKZF1	CD7, CD99, CD34, CD33, CD38, CD13dim, CD117dim	95.4
	036	T-LBL	M/29	3	Y	N	N	0.5	0.28	0	Diffused	ASXL1, JAK1, JAK3	cCD3, CD7, CD38, TDT, CD99dim, CD2dim, CD5dim	90
	037	T-LBL	M/32	4	N	N	Y	1.5	0.6	0	Mediastinum, bulky disease*	TP53, NOTCH1, IKZF1	CD5, CD7, CD8, CD34, CD99, CD1a, CD10dim, CD38, CD56, CD4dim	48.4
	038	T-LBL	F/32	3	N	N	Y	0	0	0	Diffused	PIK3R1, ZBTB7A, KIT	CD3, CD7, CD5, CD4, CD99, CD1a, CD34	90
	039	T-LBL	M/28	3	N	N	N	0.5	0.44	0	Diffused, bulky disease*	JAK1, JAK3, NOTCH1	cCD3, CD2, 99, CD10, CD38, CD48dim	90
	040	NK-T	M/53	4	N	N	Y	0	0	6	No	ND	CD7, CD56	66.4

*bulky disease >7cm
Abbreviations: AlloSCT, allogeneic stem-cell transplantation; AutoSCT, autologous stem-cell transplantation; BM, bone marrow; EMD, extramedullary disease; CNSL, central nervous system leukemia; CTCL, cutaneous T-cell lymphoma; F, female; HSTCL, hepatosplenic T-cell lymphoma; M, male; MEITL, monomorphic epitheliotropic intestinal T-cell lymphoma; ND, Not detected; NK-T/NK/T cell lymphoma; SS, sézary syndrome; T-ALL/LBL, T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma;

Table S2. CD7 CAR T products

Phase	Dose level	No.	Diagnostic	T-cell Origin	HLA Match	Actual Dose (10 ⁵ /kg)	Transduction Rate	Cell Viability (%)	Cryopreserved Prior to Infusion	Quality Control (endotoxin detection, mycoplasma test and microscopy)
Ia	1×10 ⁴ (±30%)/kg	001	T-LBL	Auto	-	0.88	31.80%	54.10%	No	Qualified
		002	T-LBL	Donor	MUD	0.77	80.90%	65.62%	No	Qualified
		003	T-LBL	Auto	-	1.24	37.80%	64.10%	No	Qualified
	5×10 ⁴ (±30%)/kg	004	T-LBL	Auto	-	0.42	44.80%	64.77%	No	Qualified
		005	T-LBL	Auto	-	0.38	66.80%	55.11%	No	Qualified
		006	SS	Auto	-	0.4	50.10%	63.04%	No	Qualified
	1×10 ⁵ (±30%)/kg	007	T-LBL	Donor	MUD	1.3	71.70%	66.00%	No	Qualified
		008	T-LBL	Auto	-	1	51.00%	76.00%	No	Qualified
		009	T-LBL	Donor	HID	0.75	76.40%	64.00%	No	Qualified
Ib	1×10 ⁵ (±30%)/kg	010	T-LBL	Donor	HID	1.03	76.40%	72.50%	No	Qualified
		011	T-LBL	Auto	-	0.7	64.90%	62.80%	No	Qualified
		012	HSTCL	Donor	HID	1.26	68.90%	54.10%	No	Qualified
		013	T-LBL	Auto	-	1	60.00%	68.30%	No	Qualified
		014	T-LBL	Auto	-	1	60.20%	70.70%	No	Qualified
		015	MEITL	Auto	-	1.12	58.00%	71.60%	No	Qualified
		016	T-LBL	Donor	MRD	1.16	56.00%	57.50%	No	Qualified
		017	T-LBL	Donor	HID	1	71.80%	66.20%	No	Qualified
		018	T-LBL	Donor	HID	1	60.00%	70.10%	No	Qualified
		019	T-LBL	Donor	HID	1	70.10%	78.40%	No	Qualified
		020	CTCL	Auto	-	0.74	56.30%	60.70%	No	Qualified
		021	T-LBL	Auto	-	1	55.90%	65.20%	No	Qualified
		022	T-LBL	Auto	-	1	84.20%	65.70%	No	Qualified
		023	T-LBL	Donor	MUD	1.2	77.70%	66.90%	No	Qualified
		024	T-LBL	Auto	-	1.1	70.50%	73.00%	No	Qualified
		025	T-LBL	Auto	-	1.24	62.10%	66.70%	No	Qualified
		026	T-LBL	Auto	-	1.14	63.50%	56.30%	No	Qualified
		027	T-LBL	Donor	HID	1.25	84.40%	65.70%	No	Qualified
		028	T-LBL	Auto	-	1	71.90%	80.50%	No	Qualified
		029	T-LBL	Donor	HID	1.28	76.00%	68.90%	No	Qualified
		030	T-LBL	Auto	-	1.2	75.00%	65.50%	No	Qualified
		031	T-LBL	Auto	-	1	84.00%	66.30%	No	Qualified
		032	T-LBL	Auto	-	1.28	89.00%	84.50%	No	Qualified
		033	T-LBL	Auto	-	1.3	74.00%	80.90%	No	Qualified
		034	T-ALL	Donor	MRD	2	79.00%	76.50%	No	Qualified
		035	T-ALL	Donor	MRD	1.24	60.00%	72.00%	No	Qualified
		036	T-LBL	Auto	-	1.26	78.00%	82.50%	No	Qualified
		037	T-LBL	Donor	MRD	1	72.50%	75.60%	No	Qualified
		038	T-LBL	Donor	HID	1	71.90%	50.50%	No	Qualified
		039	T-LBL	Auto	-	1.24	82.90%	70.50%	No	Qualified
		040	NK-T	Donor	HID	1	66.50%	73.00%	No	Qualified

Abbreviations: Auto, autologous CD7-CART; CTCL, cutaneous T-cell Lymphoma; Donor, donor-derived CD7-CART; HID, haploidentical donor; HSTCL, hepatosplenic T-cell lymphoma; MEITL, monomorphic epitheliotropic intestinal T-cell lymphoma; MRD, matched related donor; MUD, matched unrelated donor; NK-T, NK/T cell lymphoma; SS, sézary syndrome; T-ALL/LBL, T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma;

Phase	Dose	No.	T-cell Origin	BM	CNS	EMD	Before lympho-			After CAR T-			Interventions	Time of recovering		
							Neutropenia	Anemia	Thrombocytopenia	Neutropenia	Anemia	Thrombocytopenia		Neutropenia	Anemia	Thrombocytopenia
Ia	1×10 ⁴ (±30%)kg	001	Auto	67.86	0	Mediastinum	3	3	4	4	3	4	rhG-CSF	72	89	83
		002	Donor	2.3	0	Diffused	0	1	0	1	2	2	No	NA	NA	NA
		003	Auto	0.37	0.37	Diffused	1	2	1	4	3	4	rhG-CSF	14	13	13
	5×10 ⁴ (±30%)kg	004	Auto	4.7	0	Diffused	1	2	3	4	3	4	rhG-CSF	25	65	14
		005	Auto	37.39	25	Mediastinum	1	3	0	4	3	4	rhG-CSF	21	18	32
		006	Auto	11.87	0	Diffused	2	2	3	4	3	4	rhG-CSF	23	25	35
	1×10 ⁵ (±30%)kg	007	Donor	0	0	Mediastinum	2	2	1	4	3	2	rhG-CSF	18	14	NA
		008	Auto	20.79	0	Diffused	2	2	3	4	3	4	rhG-CSF	23	15	21
		009	Donor	85.61	13.6	Diffused	4	2	4	4	3	4	rhG-CSF	18	25	21
		010	Donor	49.21	4.32	No	4	3	4	4	3	4	CD34+**	21	45	NR
Ib	1×1 ¹⁰⁵ (±30%)kg	011	Auto	0.4	0	Diffused	4	3	3	4	3	4	rhG-CSF	NR	23	26
		012	Donor	1.57	0	Diffused	4	3	4	4	4	4	CD34+**	18	14	77
		013	Auto	95.76	0	Diffused	4	3	4	4	4	4	rhG-CSF	36	30	35
		014	Auto	0	0	Diffused	4	3	4	4	4	4	rhG-CSF	35	27	37
		015	Auto	0	0	Intestinal tract, bulky	2	3	0	4	3	1	rhG-CSF	16	18	NA
		016	Donor	0	5.98	Diffused, bulky disease*	4	3	4	4	3	4	rhG-CSF	17	18	NR
		017	Donor	98.42	0	No	2	3	3	4	3	4	CD34+**	70	NR	NR
		018	Donor	3.6	0	Back of the eye, the face	2	2	2	4	3	4	rhG-CSF	69	176	NR
		019	Donor	0.12	34.81	No	2	1	0	4	1	2	rhG-CSF	8	NA	NA
		020	Auto	1.2	0	Diffused	1	1	0	4	1	1	rhG-CSF	25	NA	14
		021	Auto	91.25	44.12	Diffused	4	3	3	4	3	4	AlloSCT	NA	NA	NA
		022	Auto	8.06	0	No	1	3	2	4	3	4	rhG-CSF	19	28	21
		023	Donor	1.3	0	Diffused	4	3	4	4	3	4	AlloSCT	NA	NA	NA
		024	Auto	0.7	0	Diffused	1	1	2	3	1	3	rhG-CSF	14	NA	10
		025	Auto	12	0	Diffused	1	3	3	4	3	4	rhG-CSF	14	14	NR
		026	Auto	66.5	0	No	1	1	0	4	2	3	rhG-CSF	7	NA	8
		027	Donor	0	0	Diffused	4	3	4	4	3	4	rhG-CSF	23	28	38
		028	Auto	25.6	13.64	Diffused	4	2	2	4	3	4	rhG-CSF	59	63	61
		029	Donor	0	0	Diffused	0	0	0	4	1	2	rhG-CSF	23	NA	NA
		030	Auto	3.2	0	No	0	2	0	4	3	4	rhG-CSF	7	15	11
		031	Auto	0.2	0	Diffused	4	3	4	4	3	4	AlloSCT	NA	NA	NA
		032	Auto	38.18	0	No	2	1	0	4	3	3	rhG-CSF	34	32	26
		033	Auto	36.22	0	Diffused	1	3	4	4	3	4	rhG-CSF	58	27	56
		034	Donor	0	0	Testicle	1	1	2	4	2	3	CD34+**	23	NA	24
		035	Donor	0.07	0.03	Diffused	0	2	1	4	3	4	CD34+**	20	17	23
		036	Auto	0.28	0	Diffused	0	3	3	4	4	4	AlloSCT	NA	NA	NA
		037	Donor	0.6	0	Mediastinum, bulky	2	3	4	4	3	3	rhG-CSF	NR	NR	NR
		038	Donor	0	0	Diffused	4	4	4	4	4	4	rhG-CSF	NR	NR	NR
		039	Auto	0.44	0	Diffused, bulky disease*	0	3	0	4	3	4	rhG-CSF	54	18	60
		040	Donor	0	6	No	4	3	0	4	3	4	CD34+**	41	42	34

*bulky disease >7cm; CD34+**, positively selected CD34+ stem cell infusion;
Abbreviations:Auto,autologous CD7-CART;AlloSCT, allogeneic stem-cell transplantation;BM,bone Marrow;CNSL,central nervous system leukemia;
Donor, donor-derived CD7-CART; EMD,extramedullary disease;NA, not applicable; NR,not reached; rhG-CSF, recombinant human granulocyte colony stimulating factor. Hematologic events were graded according to CTCAE v5.0.

Table S4. Comprehensive baseline characteristics, treatment, and response of individual patients

Phase	Dose	no.	Diagnostic	Age/sex	prior lines of therapy	Refractory	Previous autoHSCT	Previous alloHSCT	The interval between the previous alloHSCT and CAR-T (M)	T-cell Origin	CRS	ICANS	GVHD	Cytopenia	Infection	Response	Post-transplantation	The interval between the post alloHSCT and CAR-T (M)	Donor	Relapse	CD7 Expression (%) at relapse	outcome
Ia	1×10 ⁴ (±30%)k/g	001	T-LBL	F/72	3	N	N	N	-	Auto	1	0	-	4	4	CR	-	-	-	N	-	Died of infection
		002	T-LBL	M/40	2	N	N	Y	20	Dornor	1	0	0	1	3	CR	-	-	-	N	-	Remission and in follow-up
		003	T-LBL	M/28	2	N	N	N	-	Auto	0	0	-	4	1	NR	-	-	-	-	55	Died of relapse
	5×10 ⁴ (±30%)k/g	004	T-LBL	F/57	2	N	N	N	-	Auto	1	0	-	4	1	CR	-	-	-	N	-	Remission and in follow-up
		005	T-LBL	M/53	2	N	Y	N	-	Auto	1	0	-	4	3	CR	AlloSCT	2	HID	N	-	Died of infection
		006	SS	M/56	3	N	N	N	-	Auto	1	0	-	4	2	PR	-	-	-	Y	0	Died of relapse
	1×10 ⁵ (±30%)k/g	007	T-LBL	M/31	4	N	Y	Y	15	Dornor	0	0	0	4	0	CR	-	-	-	Y	0	Died of relapse
		008	T-LBL	M/18	3	N	N	N	-	Auto	1	0	-	4	1	CR	AlloSCT	2	HID	N	-	Remission and in follow-up
		009	T-LBL	M/29	3	N	N	Y	17	Dornor	2	0	0	4	3	PR	AlloSCT	8	HID	N	-	Died of infection
Ib	1×10 ⁵ (±30%)k/g	010	T-LBL	M/32	4	N	N	Y	9	Dornor	3	4	0	4	3	CR	-	-	-	N	-	Died of infection
		011	T-LBL	F/31	2	Y	N	N	-	Auto	1	0	-	4	3	PD	-	-	-	-	95	Died of relapse
		012	HSTCL	M/19	3	N	N	Y	20	Dornor	3	0	0	4	4	CR	-	-	-	Y	33.8	Died of relapse
		013	T-LBL	M/39	2	Y	N	N	-	Auto	1	0	-	4	3	CR	AlloSCT	2	HID	N	-	Died of infection
		014	T-LBL	M/31	4	N	N	N	-	Auto	1	0	-	4	3	CR	AlloSCT	1	HID	N	-	Remission and in follow-up
		015	MEITL	F/53	2	N	N	N	-	Auto	1	0	-	4	3	PR	AutoSCT	11	-	Y	0	Died of relapse
		016	T-LBL	M/32	3	N	N	Y	12	Dornor	1	0	1	4	3	PR	-	-	-	Y	0	Died of relapse
		017	T-LBL	M/35	4	N	N	Y	15	Dornor	1	0	0	4	3	CR	-	-	-	N	-	Died of infection
		018	T-LBL	M/29	3	N	N	Y	8	Dornor	1	0	0	4	3	CR	-	-	-	N	-	Died of infection
		019	T-LBL	M/28	3	N	N	Y	27	Dornor	1	0	0	4	1	CR	AlloSCT	5	HID	Y	0	Died of relapse
		020	CTCL	F/34	3	N	N	N	-	Auto	1	0	-	4	3	CR	AlloSCT	3	MUD	N	-	Remission and in follow-up
		021	T-LBL	F/46	3	N	N	N	-	Auto	1	0	-	4	3	CR	AlloSCT	1.5	HID	Y	95.8	Survival with disease
		022	T-LBL	F/30	3	N	Y	N	-	Auto	1	0	-	4	3	CR	AlloSCT	2	MUD	N	-	Remission and in follow-up
		023	T-LBL	M/25	3	N	N	Y	9	Dornor	2	0	0	4	3	CR	AlloSCT	1.5	HID	N	-	Remission and in follow-up
		024	T-LBL	F/24	4	N	N	N	-	Auto	1	0	-	3	2	CR	AlloSCT	2	HID	N	-	Remission and in follow-up
		025	T-LBL	M/22	3	N	N	N	-	Auto	1	0	-	4	2	PD	-	-	-	-	90	Died of relapse
		026	T-LBL	M/33	3	N	Y	N	-	Auto	2	1	-	4	4	CR	AlloSCT	1.7	MUD	N	-	Remission and in follow-up
		027	T-LBL	F/20	3	N	N	Y	6	Dornor	1	0	0	4	3	CR	AlloSCT	2	MUD	Y	0	Died of relapse
		028	T-LBL	F/31	3	N	N	N	-	Auto	1	0	-	4	3	PR	AlloSCT	1.5	HID	Y	99	Died of relapse
		029	T-LBL	M/40	4	N	N	Y	28	Dornor	0	0	0	4	0	CR	-	-	-	N	-	Remission and in follow-up
		030	T-LBL	F/67	2	N	N	N	-	Auto	1	0	-	4	2	CR	-	-	-	Y	0	Died of relapse
		031	T-LBL	M/27	3	N	N	N	-	Auto	1	0	-	4	4	CR	AlloSCT	1.5	HID	N	-	Died of infection
		032	T-ALL	F/47	2	Y	N	N	-	Auto	1	0	-	4	1	CR	AlloSCT	2	HID	N	-	Remission and in follow-up
		033	T-LBL	M/18	5	N	Y	N	-	Auto	1	0	-	4	4	CR	AlloSCT	6	HID	N	-	Died of GI hemorrhage
		034	T-LBL	M/20	2	N	N	Y	3	Dornor	1	0	1	4	3	CR	-	-	-	N	-	Died of infection
		035	T-ALL	M/49	4	N	N	Y	17	Dornor	1	0	0	4	3	CR	-	-	-	N	-	Lost to follow-up
		036	T-LBL	M/29	3	Y	N	N	-	Auto	1	0	-	4	3	CR	AlloSCT	1.5	HID	N	-	Remission and in follow-up
		037	T-LBL	M/32	4	N	N	Y	7	Dornor	1	0	1	4	4	CR	-	-	-	N	-	Died of infection
		038	T-LBL	F/32	3	N	N	Y	6	Dornor	1	0	2	4	4	PR	-	-	-	N	-	Died of infection
		039	T-LBL	M/28	3	N	N	N	-	Auto	1	0	-	4	3	CR	AlloSCT	1.5	HID	N	-	Remission and in follow-up
		040	NK-T	M/53	4	N	N	Y	11	Dornor	1	0	0	4	3	CR	-	-	-	Y	0	Died of relapse

Abbreviations: AlloSCT, allogeneic stem-cell transplantation; Auto, autologous CD7-CART; AutoSCT, autologous stem-cell transplantation; BM, bone marrow; CNSL, central nervous system leukemia; CRS, cytokine release symptom; CR, complete remission; CTCL, cutaneous T-cell lymphoma; Donor, donor-derived CD7-CART; EMD, extramedullary disease; F, female; GVHD, graft-versus-host disease; HID, haploidentical donor; HSCT, hepato脾enic T-cell lymphoma; ICANS, immune effector cell associated neurotoxicity syndrome; M, male; MEITL, monomorphic epitheliotropic intestinal T-cell lymphoma; MRD, matched related donor; MUD, matched unrelated donor; ND, Not detected; NK-T, NK/T cell lymphoma; NR, no response; PD, progressive disease; PR, partial remission; SS, sézary syndrome; T-ALL/LBL, T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma;